Sciwind opens a Phase 3 of ecnoglutide in knee osteoarthritis

Hangzhou Sciwind Biosciences has moved a Phase 3 trial of ecnoglutide from "not yet recruiting" to "recruiting," opening enrollment for participants who have both obesity and knee osteoarthritis ^[1]. The status change is the kind of registry update that can otherwise disappear from public view once ClinicalTrials.gov overwrites the old listing ^[1].

Ecnoglutide is a GLP-1 receptor agonist already cleared in China, where it won approval for type 2 diabetes in January 2026 and for chronic weight management in March 2026 ^[2]. In February 2026, Pfizer signed a deal worth up to $495 million for the rights to commercialize ecnoglutide in China ^[2]. A head-to-head trial presented in June 2026 reported that ecnoglutide produced 35% greater weight loss than semaglutide, though the sources do not specify the trial design, dose, or duration behind that figure ^[2].

The new osteoarthritis trial puts Sciwind on ground that Eli Lilly has already tested with its triple agonist retatrutide. Lilly's TRIUMPH-4 knee osteoarthritis study delivered the company's first successful Phase 3 readout in December 2025 ^[2]. Lilly followed that with pivotal obesity results from TRIUMPH-1 in May 2026, reporting weight loss of up to 30.3% at two years, described as the highest reported to date among injectable obesity drugs in late-stage trials ^[2]. Lilly has said it expects seven more Phase 3 retatrutide readouts in 2026 ^[2].

The sources do not say whether Sciwind has filed, or plans to file, for U.S. approval of ecnoglutide for either diabetes, obesity, or osteoarthritis. Ecnoglutide's approvals to date are limited to China, and no FDA submission is mentioned in the available material ^[2].

Why it matters for patients

Knee osteoarthritis is common in people with obesity, and extra body weight adds mechanical stress to already damaged joints. A GLP-1 drug that is tested specifically in people who have both conditions could eventually offer evidence about whether weight loss from these medications translates into measurable joint benefits, not just lower body weight. Right now, though, this trial is only entering the recruiting stage, meaning results are likely years away.

For U.S. readers, it is also worth noting that ecnoglutide is not an approved or available drug in the United States. Its approvals so far are in China, and its U.S. availability, price, or timeline are not addressed in the sources. Patients interested in GLP-1 options for weight management and joint pain currently have access only to drugs approved by the FDA, such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), and to trial data from candidates like retatrutide, which has posted Phase 3 results in both obesity and knee osteoarthritis but is likewise not yet FDA-approved ^[2].

What happens next

The Sciwind knee osteoarthritis trial has just opened for enrollment, so no results are expected soon ^[1]. Lilly's retatrutide program has more results due within 2026, including additional Phase 3 readouts beyond the TRIUMPH-1 and TRIUMPH-4 studies already reported ^[2]. Whether Sciwind or Pfizer will bring ecnoglutide to U.S. regulators, and on what timeline, is not addressed in the available sources and remains unknown.